Holen Sie sich die Stockscreener-App
3.62
1.11%
-0.05
Schlusskurs vom Vortag:
$3.67
Offen:
$3.67
24-Stunden-Volumen:
193.24K
Relative Volume:
0.15
Marktkapitalisierung:
$299.70M
Einnahmen:
$7.05M
Nettoeinkommen (Verlust:
$-30.43M
KGV:
-4.9366
EPS:
-0.7333
Netto-Cashflow:
$21.84M
1W Leistung:
-8.12%
1M Leistung:
-10.39%
6M Leistung:
+91.02%
1J Leistung:
+155.58%
1-Tages-Spanne:
$3.59
$3.696
1-Wochen-Bereich:
$3.5713
$4.00
52-Wochen-Spanne:
$1.18
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Firmenname
Proqr Therapeutics N V
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie PRQR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PRQR | 3.62 | 299.70M | 7.05M | -30.43M | 21.84M | -0.7333 |
| VRTX | 449.95 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.89 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.15 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.33 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-30 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Herabstufung | Stifel | Buy → Hold |
| 2022-02-01 | Eingeleitet | Raymond James | Strong Buy |
| 2021-05-03 | Eingeleitet | Stifel | Buy |
| 2021-03-25 | Bestätigt | Citigroup | Buy |
| 2020-11-03 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-12-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-11-15 | Eingeleitet | Citigroup | Buy |
| 2018-09-19 | Eingeleitet | Evercore ISI | Outperform |
| 2017-09-26 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-06-20 | Eingeleitet | Chardan Capital Markets | Neutral |
| 2014-10-15 | Eingeleitet | Deutsche Bank | Buy |
| 2014-10-13 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten
RNA Editing Market Top Companies StudyProQR Therapeutics NV, - openPR
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageTime to Sell? - MarketBeat
ProQR Therapeutics NV (FRA:0PQ) Total Inventories : €0.00 Mil (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year EBITDA Growth Rate : 31.80% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (FRA:0PQ) 3-Year Book Growth Rate : -26.20% (As of Sep. 2024) - GuruFocus.com
ProQR Therapeutics NV (MEX:PRQR) Cash Flow from Financing : MXN-38.6 Mil (TTM As of Jun. 2024) - GuruFocus.com
Chardan Capital Issues Pessimistic Outlook for PRQR Earnings - Defense World
What is Chardan Capital's Forecast for PRQR FY2024 Earnings? - MarketBeat
ProQR: Q3 Earnings Snapshot - San Francisco Chronicle
ProQR Therapeutics (NASDAQ:PRQR) Price Target Raised to $10.00 at HC Wainwright - MarketBeat
ProQR Therapeutics NV earnings beat, revenue fell short of estimates - Investing.com
ProQR Therapeutics NV earnings beat, revenue fell short of estimates By Investing.com - Investing.com UK
PRQRProQR Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
ProQR Announces Third Quarter 2024 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN
ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire
ProQR Announces Major Share Offering Agreement - TipRanks
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM
Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com
ProQR launches public offering to fund RNA therapy research - Investing.com India
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan
ProQR Therapeutics announces public offering of ordinary shares - MSN
ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance
Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Best Momentum Stocks to Buy for October 2nd - Yahoo Finance
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
Finanzdaten der Proqr Therapeutics N V-Aktie (PRQR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):